Characterization of


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 14 02 2020
accepted: 19 05 2020
entrez: 28 7 2020
pubmed: 28 7 2020
medline: 7 4 2021
Statut: epublish

Résumé

Subunit vaccines are theoretically safe and easy to manufacture but require effective adjuvants and delivery systems to yield protective immunity, particularly at critical mucosal sites such as the lung. We investigated nanolipoprotein particles (NLPs) containing the Toll-like receptor 4 agonist monophosphoryl lipid A (MPLA) as a platform for intranasal vaccination against

Identifiants

pubmed: 32714323
doi: 10.3389/fimmu.2020.01264
pmc: PMC7344197
doi:

Substances chimiques

Adjuvants, Immunologic 0
Anthrax Vaccines 0
Antibodies, Bacterial 0
Lipid A 0
Vaccines, Subunit 0
monophosphoryl lipid A MWC0ET1L2P

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1264

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI093493
Pays : United States

Informations de copyright

Copyright © 2020 Weilhammer, Dunkle, Boone, Gilmore, Khemmani, Peters, Hoeprich, Fischer, Blanchette, Driks and Rasley.

Références

J Immunol. 2005 Aug 15;175(4):2244-51
pubmed: 16081792
Microbiol Spectr. 2015 Oct;3(5):
pubmed: 26542035
J Bacteriol. 2004 Jan;186(2):566-9
pubmed: 14702325
Vaccine. 2014 Jan 9;32(3):327-37
pubmed: 24295808
Curr Clin Top Infect Dis. 2000;20:335-49
pubmed: 10943532
Infect Immun. 2009 Mar;77(3):1197-207
pubmed: 19114543
Trends Immunol. 2009 Jan;30(1):23-32
pubmed: 19059004
Protein Expr Purif. 2006 Apr;46(2):483-8
pubmed: 16290005
Environ Int. 2015 Dec;85:133-46
pubmed: 26386727
JAMA. 1999 Dec 8;282(22):2104-6
pubmed: 10591317
Cell Mol Life Sci. 2008 Oct;65(20):3231-40
pubmed: 18668203
Biochem Biophys Res Commun. 2012 May 4;421(2):323-8
pubmed: 22507985
Annu Rev Immunol. 2016 May 20;34:575-608
pubmed: 27168245
Vaccine. 2008 Sep 8;26(38):4927-39
pubmed: 18657585
PLoS One. 2014 Mar 27;9(3):e93342
pubmed: 24675794
J Bacteriol. 2009 Dec;191(24):7587-96
pubmed: 19837802
Mol Microbiol. 2007 Apr;64(2):359-67
pubmed: 17493122
Infect Immun. 2002 Feb;70(2):661-4
pubmed: 11796596
Immunology. 2006 Jan;117(1):78-88
pubmed: 16423043
FEMS Microbiol Lett. 2008 Dec;289(1):110-7
pubmed: 19054101
ChemMedChem. 2013 Mar;8(3):360-76
pubmed: 23316023
Front Biosci (Landmark Ed). 2009 Jan 01;14:4516-24
pubmed: 19273366
J Bacteriol. 2007 Sep;189(18):6704-13
pubmed: 17644587
World J Clin Cases. 2015 Jan 16;3(1):20-33
pubmed: 25610847
J Bacteriol. 2007 Feb;189(3):691-705
pubmed: 17114257
Biomaterials. 2013 Dec;34(38):10305-18
pubmed: 24075406
Bioconjug Chem. 2010 Jul 21;21(7):1321-30
pubmed: 20586461
Vaccine. 2017 Mar 13;35(11):1475-1481
pubmed: 28214044
J Bacteriol. 2003 Mar;185(6):1903-10
pubmed: 12618454
J Immunol. 2007 Mar 1;178(5):2646-50
pubmed: 17312104
Clin Vaccine Immunol. 2009 Dec;16(12):1709-19
pubmed: 19793898
Clin Immunol. 2004 Apr;111(1):1-15
pubmed: 15093546
PLoS One. 2010 Jul 19;5(7):e11643
pubmed: 20657844
Infect Immun. 2007 Nov;75(11):5240-7
pubmed: 17785478
J Am Chem Soc. 2007 Nov 21;129(46):14348-54
pubmed: 17963384
J Bacteriol. 2005 Sep;187(17):5868-76
pubmed: 16109927
Vaccine. 2007 Jul 26;25(30):5467-84
pubmed: 17227687
Microb Pathog. 2011 Oct;51(4):255-61
pubmed: 21729749
J Med Microbiol. 2012 Oct;61(Pt 10):1380-1392
pubmed: 22767539
J Med Microbiol. 2002 Oct;51(10):821-831
pubmed: 12435060
N Engl J Med. 1999 Sep 9;341(11):815-26
pubmed: 10477781
Mol Microbiol. 2002 Jul;45(1):169-78
pubmed: 12100557
Vaccine. 2006 May 22;24(21):4569-71
pubmed: 16157424
J Appl Microbiol. 1999 Aug;87(2):304
pubmed: 10475975
Bioconjug Chem. 2009 Mar 18;20(3):460-5
pubmed: 19239247
Nat Rev Immunol. 2018 Jan;18(1):46-61
pubmed: 29063907
Front Immunol. 2013 Jul 12;4:185
pubmed: 23874333
J Am Chem Soc. 2013 Feb 13;135(6):2044-7
pubmed: 23331082
Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10638-43
pubmed: 20479237
Bioconjug Chem. 2010 Jun 16;21(6):1018-22
pubmed: 20509624
Infect Immun. 2007 Aug;75(8):4020-9
pubmed: 17502384

Auteurs

Dina R Weilhammer (DR)

Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.

Alexis D Dunkle (AD)

Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.

Tyler Boone (T)

Department of Microbiology and Immunology, Loyola University Medical Center, Chicago, IL, United States.

Sean F Gilmore (SF)

Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.

Mark Khemmani (M)

Department of Microbiology and Immunology, Loyola University Medical Center, Chicago, IL, United States.

Sandra K G Peters (SKG)

Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.

Paul D Hoeprich (PD)

Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.

Nicholas O Fischer (NO)

Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.

Craig D Blanchette (CD)

Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.

Adam Driks (A)

Department of Microbiology and Immunology, Loyola University Medical Center, Chicago, IL, United States.

Amy Rasley (A)

Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH